Physician profile
Ramon A Rosa
NPI 1194792903
$12,119.04
in general payments reported to CMS, 2019-2025
40 companies · $1,664 in 2025
The $1,664 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,703 · 2020: $609 · 2021: $1,554 · 2022: $1,985 · 2023: $1,782 · 2024: $1,821 · 2025: $1,664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,177 · Education: $90.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,176.66 |
| Education | $90.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,389.54 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $1,210.84 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,031.50 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $986.26 | 2019-2025 | Brilinta, Farxiga |
| Pfizer INC. | $926.27 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $735.02 | 2019-2024 | Xarelto |
| Medtronic Vascular, INC. | $581.66 | 2019-2020 | |
| Medtronic, INC. | $525.56 | 2021-2025 | Micra, Aurora Ev-Icd Mri Surescan, Corevalve Evolut R |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $481.73 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $445.27 | 2019-2024 | Jardiance |
| Boston Scientific Corporation | $389.91 | 2019-2025 | Synergy, Watchman |
| Regeneron Healthcare Solutions, INC. | $351.17 | 2019 | |
| Novo Nordisk INC | $341.55 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $334.16 | 2021-2025 | Verquvo |
| Abbott Laboratories | $294.30 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Gallant, Aveir |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramon Rosa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.